Small Molecules

9 March 2013

Results from HPS2-THRIVE Study of TREDAPTIVE (extended-release niacin/laropiprant) Presented at American College of Cardiology Scientific Sessions

9 March 2013

Janssen Launches EXPLORER, Global Cardiovascular Research Program, Beginning with Five New Studies in Patients with Unmet Medical Needs

9 March 2013

Prana Details Data Showing That PBT2 Reduces Cognitive Impairment Caused by Tau Protein Accumulation

7 March 2013

Janssen Submits European Marketing Authorisation Application for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes

7 March 2013

New Superiority Trial Showed LIVALO (pitavastatin) 4 mg Provided Significantly Greater LDL-C Reduction in HIV-Infected Adults with Dyslipidemia versus Pravastatin 40 mg

7 March 2013

ViiV Healthcare presents data from Phase III study of dolutegravir vs raltegravir in treatment-experienced adults with HIV-1

6 March 2013

Results from a phase IIa study evaluating Simeprevir and Sofosbuvir in prior null responder Hepatitis C patients have been presented at CROI

6 March 2013

First Patient Enrolled in Third Phase III Study of Oral Laquinimod for Relapsing-Remitting Multiple Sclerosis

6 March 2013

Depomed Provides Update on SEFELSA™ FDA Advisory Committee

6 March 2013

Belinostat BELIEF trial exceeds primary endpoint with encouraging response rate

6 March 2013

Nuvo Research announces FDA response to PENNSAID 2% NDA

6 March 2013

Tobira Therapeutics Presents Positive Phase 2b Clinical Results For Cenicriviroc in Treatment-Naive HIV Infection in Late Breaker Session at CROI

6 March 2013

Gilead Announces Full 24-Week Phase 2 Results for Once-Daily Single Tablet HIV Regimen Containing Novel Prodrug Tenofovir Alafenamide (TAF)

6 March 2013

SymBio Announces Completion of Patient Enrollment of TREAKISYM(R) (SyB L-0501) Phase II Trial in Frontline Low-Grade Non-Hodgkin’s Lymphoma and Mantle Cell Lymphoma

6 March 2013

Progenics Pharmaceuticals’ Novel Small Molecule Drugs Targeting PSMA Successfully Visualize Prostate Cancer

6 March 2013

ZIOPHARM Oncology Announces Initiation of Indiana University-Sponsored Phase 2 Study of Palifosfamide in Recurrent and Incurable Germ Cell (Testicular and Ovarian) Tumors

5 March 2013

AcelRx Top-line Data Show Primary Endpoint Achieved in Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Post-Operative Pain in Major Open Abdominal Surgery Patients

5 March 2013

NeuroDerm Announces Positive Results of a Phase I Study of ND0612 for the Treatment of Parkinson’s Disease

5 March 2013

Shape Pharmaceuticals Provides Update on SHP-141 Topical HDAC Inhibitor Clinical Development for Cutaneous T Cell Lymphoma

5 March 2013

PsiOxus Therapeutics Completes Patient Enrollment for Phase II Wasting Disease Therapeutic MT-102

5 March 2013

VIMPAT (lacosamide) generates positive results in US Phase 3 monotherapy study

5 March 2013

U.S. FDA Issues Complete Response Letter for Bayer’s Xarelto (Rivaroxaban) for the Reduction of Cardiovascular Events in Patients with ACS

4 March 2013

Tosedostat OPAL Study in Acute Myeloid Leukemia Published in Lancet Oncology

4 March 2013

Interim results from CHEST-2 study support benefits of Bayer’s Riociguat as demonstrated in Phase III CHEST-1 study

4 March 2013

VX-787 Showed Significant Antiviral Activity and Reduced the Severity and Duration of Influenza Symptoms in Phase 2 Challenge Study

4 March 2013

First interim results from a phase IIa study evaluating an all-oral regimen of Simeprevir and Sofosbuvir in prior null responder Hepatitis C patients

4 March 2013

Boehringer Ingelheim Announces Interim Results Evaluating Virologic Response Rates in HCV/HIV Co-Infected Patients Treated with Faldaprevir

3 March 2013

KYTHERA Biopharmaceuticals, Inc. Announces Positive Interim Results from Open-Label Study of ATX-101 in the Reduction of Unwanted Submental Fat (SMF) or “Double Chin”

3 March 2013

Oral Apremilast Achieves Statistical Significance for the Primary Endpoint of PASI-75 in the First Phase III Study (ESTEEM 1) in Patients with Psoriasis

3 March 2013

Anacor Pharmaceuticals Announces Positive Results from the Second Phase 3 Trial of Tavaborole for Onychomycosis

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Report Package: “Drug the Undruggable” Technologies

2023 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review

Fibroblast Activation Protein (FAP) Targeted Therapy & Companion Diagnostic Pipeline Review

IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Review

2FOR1 Report Package: Vectorized Antibody and Prodrug Antibody & Cytokine landscape analysis report package with 50% discount

Denosumab (Prolia & Xgeva) Biosimilars Pipeline Review

EpCAM-Targeted Antibodies Pipeline Review

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

GPC3-Targeted Immunotherapy Pipeline Review